Projects

Funded research projects, clinical trials and observational studies in which the group takes part.

Research projects

Projects funded through competitive national and international calls.

ProjectCancer typeFundingScopeYearPI
IMMUNEAMBITIONOptimising immunotherapy in advanced bladder cancer by inhibiting autotaxin-dependent immunosuppressionPID2024-161699OB-I00BladderAgencia Estatal de InvestigaciónNational
ImmunoUroTaxinAddressing the role of autotaxin as a new therapeutic target in urothelial bladder cancerPID2021-125385OB-I00BladderAgencia Estatal de InvestigaciónNational
Boosting immunotherapy in advanced bladder cancer by targeting autotaxin-dependent immunosuppressionPI25/00069BladderInstituto de Salud Carlos IIINational
Targeting autotaxin–lysophosphatidic acid signalling to improve the efficacy of immunotherapy in urothelial bladder cancerLABAE223471MATABladderAsociación Española Contra el CáncerNational2022Elisa Matas Rico
PrognoUroTaxinEvaluating the role of autotaxin as a prognostic factor in bladder cancerCNS2022-135994BladderAgencia Estatal de InvestigaciónNational2022Elisa Matas Rico
MOLCARUTUCComprehensive genomic characterisation of upper urinary tract urothelial carcinoma and paired bladder recurrencesAC18/00021Upper urinary tract BladderInstituto de Salud Carlos III (acción complementaria internacional)International
Development of diagnostic tools and biomarkers in collaboration with Mirnax BiosensRTC-2017-6501-1Agencia Estatal de Investigación (Retos-Colaboración)National2017
BRECISEBiomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement101194784ProstateUnión Europea · Horizonte EuropaInternational
SWALU23Development and validation of an automated system for prediction, diagnosis and early analysis of lower urinary tract disorders using signal processing and artificial intelligence on a smartwatchCPP2022-010045OtherAgencia Estatal de InvestigaciónNational2023Bernardo Herrera Imbroda
Clinical, radiological and genetic evaluation of patients with metastatic hormone-sensitive prostate cancer treated with new-generation antiandrogensAEU21-001 · CPC21065ProstateAsociación Española de UrologíaNational2020Elisa Matas Rico

Clinical trials

Studies evaluating new treatments in patients, grouped by cancer type.

Prostate cancer

StudyPhaseSponsorPI
ARANOTEDarolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in metastatic hormone-sensitive prostate cancerIIIBayer AGBernardo Herrera Imbroda
ARASTEPDarolutamide plus ADT versus placebo plus ADT in high-risk biochemically recurrent prostate cancerIIIBayer AGBernardo Herrera Imbroda
PROTEUSApalutamide plus ADT versus placebo plus ADT in high-risk localised or locally advanced prostate cancer in candidates for radical prostatectomy56021927PCR3011IIIJanssen-CilagBernardo Herrera Imbroda
Apalutamide in high-risk localised or locally advanced prostate cancer receiving primary radiotherapyIIIJanssen-CilagRaquel Correa Generoso
EvoPAR-Prostate02Adjuvant saruparib (AZD5305) in high-risk localised BRCA-mutated prostate cancer treated with radiotherapy and ADTIIIAstraZeneca
TEAM PCTalazoparib plus enzalutamide as first-line treatment for metastatic castration-resistant prostate cancer after progression on abirateroneIIFundación OncosurBernardo Herrera Imbroda
DE-ESCALATEIntermittent androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in the era of new androgen receptor pathway inhibitors
ADT with or without local radiotherapy and with or without abiraterone and prednisone in metastatic hormone-sensitive prostate cancerIIIUNICANCERRaquel Correa Generoso
Oral darolutamide (ODM-201) versus androgen deprivation therapy with LHRH agonists or antagonists in men without prior hormone therapyIIHospital Universitario de SalamancaBernardo Herrera Imbroda
EPI-7386 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancerI/IIESSA PharmaRocío Santos Pérez de la Blanca
PROCADEOral HC-1119 versus enzalutamide in metastatic castration-resistant prostate cancerIIIHinova PharmaceuticalsDavid Hernández Alcaraz
PEGASUSRadiotherapy plus adjuvant androgen suppression with a GnRH antagonist versus agonist in very high-risk prostate cancerEORTC-GUCG 1532IIIbEORTCAna María Otero Romero
177Lu-PSMA-I&T versus hormone therapy in metastatic castration-resistant prostate cancerIIICuriumDavid Hernández Alcaraz
Hypofractionated postoperative radiotherapy in patients with prostate cancer (multicentre study)Medical deviceGICORAna María Otero Romero

Bladder cancer

StudyPhaseSponsorPI
ABLE-22Intravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapy in BCG-unresponsive high-grade non-muscle-invasive bladder cancer with CISIIIFerring
ABLE-32Nadofaragene firadenovec versus observation in intermediate-risk non-muscle-invasive bladder cancerIIIbFerring
SunRISe-1TAR-200 with cetrelimab, TAR-200 alone or cetrelimab alone in BCG-unresponsive high-risk NMIBCIIbJanssen-CilagBernardo Herrera Imbroda
SunRISe-3TAR-200 with cetrelimab or TAR-200 alone versus intravesical BCG in BCG-naïve high-risk NMIBCIIIJanssen-CilagBernardo Herrera Imbroda
SunRISe-4TAR-200 with cetrelimab and cetrelimab monotherapy in muscle-invasive urothelial bladder carcinoma before radical cystectomyIIJanssen-CilagBernardo Herrera Imbroda
SunRISe-5TAR-200 versus intravesical chemotherapy in high-risk NMIBC recurring after BCG, in patients not eligible for cystectomyIIIJanssen-CilagBernardo Herrera Imbroda
MoonRISe-1TAR-210 erdafitinib intravesical system versus intravesical chemotherapy in intermediate-risk NMIBC with FGFR alterationsIIIJanssen-CilagBernardo Herrera Imbroda
MoonRISe-3TAR-210 versus intravesical chemotherapy in BCG-treated high-risk NMIBC with FGFR alterationsIIIJanssen-Cilag
MK-2870Intravesical sacituzumab tirumotecan (sac-TMT) in intermediate-risk NMIBCMK-2870-027I/IIMerck Sharp & DohmeBernardo Herrera Imbroda
MK-3120-003Intravesical MK-3120 in high-risk NMIBC, BCG-naïve or BCG-exposedI/IIMerck Sharp & Dohme
POTOMACDurvalumab plus BCG versus BCG alone in BCG-naïve high-risk NMIBCD419JC00001IIIAstraZenecaBernardo Herrera Imbroda
ONCOFID-P-BIntravesical paclitaxel–hyaluronic acid conjugate in BCG-unresponsive bladder carcinoma in situIIIFidia FarmaceuticiFelipe Sáez Barranquero
Intravesical eciskafusp alfa with BCG in BCG-unresponsive high-risk NMIBCBP45381I/IIRoche FarmaBernardo Herrera Imbroda
UTOPIAUGN-103 in low-grade intermediate-risk non-muscle-invasive bladder cancerIIIUroGen PharmaFelipe Sáez Barranquero
Nivolumab with or without other agents, with or without BCG, in BCG-unresponsive high-risk NMIBCCA209-9UTIIBristol Myers Squibb
Pilot study of the biological effects of vitamin D in patients with resectable urothelial carcinomaIVIGTP (Germans Trias i Pujol)Bernardo Herrera Imbroda

Other urological studies

StudyPhaseSponsorPI
URO-901-3005

Observational studies and registries

Studies of patients treated with already approved therapies in routine clinical practice.

StudyCancer typeSponsorPI
DAROLObservational study of darolutamide in non-metastatic castration-resistant prostate cancerProstateBayer HispaniaBernardo Herrera Imbroda
PROHNOSRegistry of epidemiology, treatment patterns and real-world outcomes of metastatic hormone-sensitive prostate cancer in SpainProstate
ROADReal-world outcomes of darolutamide and ADT, with or without docetaxel, in metastatic hormone-sensitive prostate cancerProstate
CAPTURETreatment patterns and outcomes in metastatic prostate cancer with and without somatic or germline homologous recombination repair gene alterationsProstate
PROVIDENCEPrediction of metastatic relapse in intermediate/high-risk localised prostate cancer from staging images and clinical variablesProstate
PROCUREPROCURE biomarker platform: PROREPAIR-B, PROSENZA, PROSTAC and PROSABI prospective studies in advanced prostate cancerProstate
HOPE-ProstateFeasibility and impact of liquid biopsy-based genomic profiling on treatment decisions in metastatic prostate cancer in SpainProstate
BLADIMIRNon-invasive tool for bladder cancer diagnosis and monitoring based on detection of miRNA in urineBladder
RECAPSpanish Prostate Cancer Registry: radiotherapy treatment in routine clinical practiceProstateSociedad Española de Oncología RadioterápicaAna María Otero Romero
PARASECTreatment patterns and long-term follow-up of prostate cancer patients who received darolutamide in the ARAMIS trialProstateApices SolucionesJuan Andrés Cantero Mellado
ArtemisPROClinical outcomes in metastatic hormone-sensitive prostate cancer treated with ADT plus apalutamide or enzalutamide in routine practiceProstateJanssen-CilagDavid Hernández Alcaraz
PINNOCAVOrganisational innovation and personalised medicine platform to optimise the care pathway of patients with bladder cancerBladder